Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Published byBernard Lewis Modified over 6 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro"— Presentation transcript:

1 Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.182
Figure 1 Selected advances in pancreatic ductal adenocarcinoma during 2017 Figure 1 | Selected advances in pancreatic ductal adenocarcinoma during Studies highlighted here include an integrated characterization of the molecular landscape of pancreatic ductal adenocarcinoma (PDAC) from The Cancer Genome Atlas (part a), which confirmed the existence of two subtypes based on molecular expression profiles with prognostic implications; a novel systemic delivery platform using inhibitory exosomes (iExosomes) to genetically target mutant KRAS in multiple preclinical PDAC models (part b); and a new standard of care, gemcitabine plus capecitabine, showed improved overall survival for the adjuvant therapy of resected PDAC (part c). lncRNA, long non-coding RNA; miRNA, microRNA; siRNA, small interfering RNA. Semaan, A. & Maitra, A. (2018) Rebooting pancreatic cancer knowledge and treatment options Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Download ppt "Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro"

Similar presentations

Margaret Tempero, M.D. Professor of Medicine University of California, San Francisco Debate: This house believes that FOLFIRINOX is the best treatment.

Margaret Tempero, M.D. Professor of Medicine University of California, San Francisco Debate: This house believes that FOLFIRINOX is the best treatment.
Discussant Slides: Title: Radiosensitivity Index Shows Promise for Predicting Outcomes with Adjuvant Radiation in Resected Pancreatic Cancer Patients Poster.

Discussant Slides: Title: Radiosensitivity Index Shows Promise for Predicting Outcomes with Adjuvant Radiation in Resected Pancreatic Cancer Patients Poster.
종양혈액내과 R4 고원진 / pf. 김시영 Rectal cancer : state of the art in 2012 Curr Opin Oncol 2012, 24:441–447.

종양혈액내과 R4 고원진 / pf. 김시영 Rectal cancer : state of the art in 2012 Curr Opin Oncol 2012, 24:441–447.
R3 이운주/Prof 맹치훈. Introduction Pancreatic adenocarcinoma is most lethal cancer, with a 5-year survival rate of less than 5%. Relapsed occurs in 80-85%

R3 이운주/Prof 맹치훈. Introduction Pancreatic adenocarcinoma is most lethal cancer, with a 5-year survival rate of less than 5%. Relapsed occurs in 80-85%
? miRNA profiling (primary vs recurrent) Between patients cohort (n=6)

? miRNA profiling (primary vs recurrent) Between patients cohort (n=6)
Figure 2 Exosome composition

Figure 2 Exosome composition
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Figure 4 Activation of clopidogrel via cytochrome P450

Figure 4 Activation of clopidogrel via cytochrome P450
Figure 1 The epigenetic landscape mediates the interplay between stressors and renal dysfunction Figure 1 | The epigenetic landscape mediates the interplay.

Figure 1 The epigenetic landscape mediates the interplay between stressors and renal dysfunction Figure 1 | The epigenetic landscape mediates the interplay.
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 6 Injection of mesenchymal stem cells in perianal fistulas

Figure 6 Injection of mesenchymal stem cells in perianal fistulas
Figure 1 Patients cured of HCV infection

Figure 1 Patients cured of HCV infection
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Figure 2 A stage-based approach to the treatment of NAFLD

Figure 2 A stage-based approach to the treatment of NAFLD
Figure 1 Gut microorganisms at the intersection of several diseases

Figure 1 Gut microorganisms at the intersection of several diseases
Figure 1 Worldwide incidence of CCA

Figure 1 Worldwide incidence of CCA
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Figure 1 Organs involved in coeliac-disease-associated autoimmunity
Figure 5 Exosomes for delivery of RNA interference therapeutics

Figure 5 Exosomes for delivery of RNA interference therapeutics
Figure 1 Biosimilar development process

Figure 1 Biosimilar development process

Similar presentations

Ads by Google